Fennec Pharmaceuticals (FENC) Research & Development (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Research & Development of $20000.0 for Q4 2025, down 60.0% year-on-year from $50000.0 in Q4 2024, and down 31.03% on a QoQ basis from $29000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Research & Development data on file, last reported at $20000.0 in Q4 2025.
- For the quarter ending Q4 2025, Research & Development fell 60.0% year-over-year to $20000.0; the trailing twelve-month figure through Dec 2025 stood at $250000.0 (down 18.57% YoY), and the FY2025 full-year result was $250000.0, down 18.57% from the prior year.
- Research & Development for Q4 2025 stood at $20000.0, down from $29000.0 in the prior quarter.
- Across five years, Research & Development topped out at $2.4 million in Q1 2021 and bottomed at $3000.0 in Q1 2024.
- The 5-year median for Research & Development is $102000.0 (2024), against an average of $456250.0.
- The widest annual swing landed in 2023, when Research & Development sank 99.72%; it then surged 3033.33% in 2025.
- A 5-year view of Research & Development shows it stood at $523000.0 in 2021, then tumbled by 77.63% to $117000.0 in 2022, then sank by 72.65% to $32000.0 in 2023, then surged by 56.25% to $50000.0 in 2024, then sank by 60.0% to $20000.0 in 2025.
- The last three Research & Development figures came in at $20000.0 (Q4 2025), $29000.0 (Q3 2025), and $107000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 94,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 157,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 117,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 1.13 Mn |
| Mar 31, 2022 | 1.44 Mn |
| Dec 31, 2021 | 523,000.00 |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 800,000.00 |
| Mar 31, 2021 | 2.42 Mn |
| Dec 31, 2020 | 1.22 Mn |
| Sep 30, 2020 | 1.37 Mn |
| Jun 30, 2020 | 1.12 Mn |
| Mar 31, 2020 | 1.39 Mn |
| Dec 31, 2019 | 1.17 Mn |
| Sep 30, 2019 | 795,000.00 |
| Jun 30, 2019 | 1.97 Mn |
| Mar 31, 2019 | 1.67 Mn |
| Dec 31, 2018 | 1.72 Mn |
| Sep 30, 2018 | 1.80 Mn |
| Jun 30, 2018 | 798,000.00 |
| Mar 31, 2018 | 689,000.00 |
| Dec 31, 2017 | 886,000.00 |
| Sep 30, 2017 | 492,000.00 |
| Jun 30, 2017 | 333,000.00 |
| Mar 31, 2017 | 225,000.00 |
| Dec 31, 2016 | 174,000.00 |
| Sep 30, 2016 | 112,000.00 |
| Jun 30, 2016 | 139,000.00 |
| Mar 31, 2016 | 47,000.00 |
| Dec 31, 2015 | 71,000.00 |
| Sep 30, 2015 | 88,000.00 |
| Jun 30, 2015 | 54,000.00 |
| Mar 31, 2015 | 43,000.00 |
| Dec 31, 2014 | 165,000.00 |
| Sep 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 72,000.00 |
| Mar 31, 2014 | 24,000.00 |
| Dec 31, 2013 | 90,000.00 |
| Sep 30, 2013 | -224,000.00 |
| Jun 30, 2013 | 554,000.00 |
| Mar 31, 2013 | 178,000.00 |
| Dec 31, 2012 | 561,000.00 |
| Sep 30, 2012 | 357,000.00 |
| Jun 30, 2012 | 860,000.00 |
| Mar 31, 2012 | 296,000.00 |
| Dec 31, 2011 | 506,000.00 |
| Sep 30, 2011 | 439,000.00 |
| Jun 30, 2011 | 234,000.00 |
| Mar 31, 2011 | 315,000.00 |
| Dec 31, 2010 | 289,000.00 |
| Sep 30, 2010 | 110,000.00 |
| Jun 30, 2010 | 146,000.00 |